Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2B, randomized, double blind, placebo-controlled, multicenter study to compare 6 dose regimens of CP-690,550 vs. placebo, each combined with methotrexate, administered for 6 months in the treatment of subjects with active rheumatoid arthritis who have had an inadequate response to methotrexate alone

Trial Profile

A phase 2B, randomized, double blind, placebo-controlled, multicenter study to compare 6 dose regimens of CP-690,550 vs. placebo, each combined with methotrexate, administered for 6 months in the treatment of subjects with active rheumatoid arthritis who have had an inadequate response to methotrexate alone

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2018

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 14 Nov 2018 Results assessing Short-, Mid-, and Long-term Effects of Tofacitinib on Lymphocytes in RA patients using data from NCT00853385, NCT01039688, NCT00147498, NCT00413660, NCT00550446, CT02147587 and NCT00413699 sub-studies), published in the Arthritis and Rheumatology
    • 31 Aug 2018 Biomarkers information updated
    • 16 Jun 2018 Results of pooled data from 4 Phase 2 trials (NCT00413660; NCT00550446; NCT00603512; NCT00687193) and 5 Phase 3 randomised, double-blind, placebo-controlled trials (ORAL Scan [NCT00847613]; ORAL Solo [NCT00814307]; ORAL Sync [NCT00856544]; ORAL Standard [NCT00853385]; ORAL Step [NCT00960440]), were presented at the 19th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top